Last updated on June 2019

A Study of CCX140-B in Subjects With FSGS


Brief description of study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Detailed Study Description

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) to be conducted in the North America, Europe and Australia. The aim of this study is to evaluate the effect of treatment with CCX140-B, a selective antagonist of C-C chemokine receptor type 2 in subjects with focal segmental glomerulosclerosis on urinary protein excretion as assessed by changes in urine protein to creatinine ratio (UPCR)

Clinical Study Identifier: NCT03536754

Find a site near you

Start Over

Northwest Louisiana Nephrology

Shreveport, LA United States
  Connect »

AKDHC

Phoenix, AZ United States
  Connect »

MGH

Boston, MA United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

East Carolina University

Greenville, NC United States
  Connect »

Rhode Island Hospital

Providence, RI United States
  Connect »

Utah Kidney Research Institute

Salt Lake City, UT United States
  Connect »

Austin Health

Heidelberg, Australia
  Connect »

CHU de Grenoble

Grenoble cedex 9, France
  Connect »

North Shore Hospital

Takapuna, New Zealand
  Connect »

Taranaki Base Hospital

New Plymouth, New Zealand
  Connect »